DETERMINATION OF THE CEREBRAL DOPAMINE-D2-RECEPTOR DENSITY BY I-123 IBZM-SPECT IN PATIENTS WITH PARKINSONS-DISEASE

被引：13

作者：

HIERHOLZER, J

CORDES, M

SCHELOSKY, L

BARZEN, G

POEWE, W

HENKES, H

KESKE, U

HOROWSKI, R

FELIX, R

机构：

[1] FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,NEUROL KLIN & POLIKLIN,W-1000 BERLIN 65,GERMANY

[2] UNIV HOMBURG SAAR,FAK MED,INST NEURORADIOL,HOMBURG,GERMANY

[3] SCHERING AG,BERLIN,GERMANY

来源：

FORTSCHRITTE AUF DEM GEBIETE DER RONTGENSTRAHLEN UND DER NEUEN BILDGEBENDEN VERFAHREN | 1992年 / 157卷 / 04期

关键词：

DOPAMINE-RECEPTORS; PARKINSONS DISEASE; BASAL GANGLIA; SPECT; I-123-IBZM;

D O I：

10.1055/s-2008-1033028

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

An alteration of the dopaminergic nigrostriatal system is believed to be the main pathogenetic factor of Parkinson's disease (PD). We report on our initial results on the determination of the post-synaptic dopamine-D2-receptor binding of I-123-IBZM in patients with PD. Drug-native patients showed a significantly higher IBZM binding in the basal ganglia as compared to patients on specific dopaminergic medication. Age, duration of the disease and the severity of the disease do not seem to influence the IBZM-receptor binding. We conclude that I-123-IBZM-SPECT is an extremely useful tool for the evaluation of the functional state of cerebral dopamine-D2-receptors.

引用

页码：390 / 398

页数：9

共 34 条

[1]

BIRKMAYER W, 1961, Wien Klin Wochenschr, V73, P787

[2]

BROWN RG, 1987, MOVEMENT DISORD, V2, P99

[3]

BRUCKE T, 1991, J CEREBR BLOOD F MET, V11, P220

[4] NOVEL NUCLEAR DIAGNOSTICS AS APPLIED PATHOPHYSIOLOGY - BASICS AND FUTURE ASPECTS [J].